257 related articles for article (PubMed ID: 18030990)
1. Profiling heparin-chemokine interactions using synthetic tools.
de Paz JL; Moseman EA; Noti C; Polito L; von Andrian UH; Seeberger PH
ACS Chem Biol; 2007 Nov; 2(11):735-44. PubMed ID: 18030990
[TBL] [Abstract][Full Text] [Related]
2. The Anti-inflammatory Protein TSG-6 Regulates Chemokine Function by Inhibiting Chemokine/Glycosaminoglycan Interactions.
Dyer DP; Salanga CL; Johns SC; Valdambrini E; Fuster MM; Milner CM; Day AJ; Handel TM
J Biol Chem; 2016 Jun; 291(24):12627-12640. PubMed ID: 27044744
[TBL] [Abstract][Full Text] [Related]
3. The dependence of chemokine-glycosaminoglycan interactions on chemokine oligomerization.
Dyer DP; Salanga CL; Volkman BF; Kawamura T; Handel TM
Glycobiology; 2016 Mar; 26(3):312-26. PubMed ID: 26582609
[TBL] [Abstract][Full Text] [Related]
4. Targeting Chemokine-Glycosaminoglycan Interactions to Inhibit Inflammation.
Crijns H; Vanheule V; Proost P
Front Immunol; 2020; 11():483. PubMed ID: 32296423
[TBL] [Abstract][Full Text] [Related]
5. Glycosaminoglycans interact selectively with chemokines and modulate receptor binding and cellular responses.
Kuschert GS; Coulin F; Power CA; Proudfoot AE; Hubbard RE; Hoogewerf AJ; Wells TN
Biochemistry; 1999 Sep; 38(39):12959-68. PubMed ID: 10504268
[TBL] [Abstract][Full Text] [Related]
6. Kinetics of chemokine-glycosaminoglycan interactions control neutrophil migration into the airspaces of the lungs.
Tanino Y; Coombe DR; Gill SE; Kett WC; Kajikawa O; Proudfoot AE; Wells TN; Parks WC; Wight TN; Martin TR; Frevert CW
J Immunol; 2010 Mar; 184(5):2677-85. PubMed ID: 20124102
[TBL] [Abstract][Full Text] [Related]
7. Chemokines have diverse abilities to form solid phase gradients.
Patel DD; Koopmann W; Imai T; Whichard LP; Yoshie O; Krangel MS
Clin Immunol; 2001 Apr; 99(1):43-52. PubMed ID: 11286540
[TBL] [Abstract][Full Text] [Related]
8. Heparin Specifically Interacts with Basic BBXB Motifs of the Chemokine CCL21 to Define CCR7 Signaling.
Artinger M; Gerken OJ; Legler DF
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675182
[TBL] [Abstract][Full Text] [Related]
9. Transferring the C-terminus of the chemokine CCL21 to CCL19 confers enhanced heparin binding.
Barmore AJ; Castex SM; Gouletas BA; Griffith AJ; Metz SW; Muelder NG; Populin MJ; Sackett DM; Schuster AM; Veldkamp CT
Biochem Biophys Res Commun; 2016 Sep; 477(4):602-606. PubMed ID: 27338641
[TBL] [Abstract][Full Text] [Related]
10. Eotaxin selectively binds heparin. An interaction that protects eotaxin from proteolysis and potentiates chemotactic activity in vivo.
Ellyard JI; Simson L; Bezos A; Johnston K; Freeman C; Parish CR
J Biol Chem; 2007 May; 282(20):15238-47. PubMed ID: 17384413
[TBL] [Abstract][Full Text] [Related]
11. Differing activities of homeostatic chemokines CCL19, CCL21, and CXCL12 in lymphocyte and dendritic cell recruitment and lymphoid neogenesis.
Luther SA; Bidgol A; Hargreaves DC; Schmidt A; Xu Y; Paniyadi J; Matloubian M; Cyster JG
J Immunol; 2002 Jul; 169(1):424-33. PubMed ID: 12077273
[TBL] [Abstract][Full Text] [Related]
12. Heparin oligosaccharides inhibit chemokine (CXC motif) ligand 12 (CXCL12) cardioprotection by binding orthogonal to the dimerization interface, promoting oligomerization, and competing with the chemokine (CXC motif) receptor 4 (CXCR4) N terminus.
Ziarek JJ; Veldkamp CT; Zhang F; Murray NJ; Kartz GA; Liang X; Su J; Baker JE; Linhardt RJ; Volkman BF
J Biol Chem; 2013 Jan; 288(1):737-46. PubMed ID: 23148226
[TBL] [Abstract][Full Text] [Related]
13. Structural basis, stoichiometry, and thermodynamics of binding of the chemokines KC and MIP2 to the glycosaminoglycan heparin.
Sepuru KM; Nagarajan B; Desai UR; Rajarathnam K
J Biol Chem; 2018 Nov; 293(46):17817-17828. PubMed ID: 30257866
[TBL] [Abstract][Full Text] [Related]
14. The gammaherpesvirus chemokine binding protein can inhibit the interaction of chemokines with glycosaminoglycans.
Webb LM; Smith VP; Alcami A
FASEB J; 2004 Mar; 18(3):571-3. PubMed ID: 14734646
[TBL] [Abstract][Full Text] [Related]
15. Chemokine-glycosaminoglycan binding: specificity for CCR2 ligand binding to highly sulfated oligosaccharides using FTICR mass spectrometry.
Yu Y; Sweeney MD; Saad OM; Crown SE; Hsu AR; Handel TM; Leary JA
J Biol Chem; 2005 Sep; 280(37):32200-8. PubMed ID: 16033763
[TBL] [Abstract][Full Text] [Related]
16. Structure and function of A41, a vaccinia virus chemokine binding protein.
Bahar MW; Kenyon JC; Putz MM; Abrescia NG; Pease JE; Wise EL; Stuart DI; Smith GL; Grimes JM
PLoS Pathog; 2008 Jan; 4(1):e5. PubMed ID: 18208323
[TBL] [Abstract][Full Text] [Related]
17. Chemokine cooperativity is caused by competitive glycosaminoglycan binding.
Verkaar F; van Offenbeek J; van der Lee MMC; van Lith LHCJ; Watts AO; Rops ALWMM; Aguilar DC; Ziarek JJ; van der Vlag J; Handel TM; Volkman BF; Proudfoot AEI; Vischer HF; Zaman GJR; Smit MJ
J Immunol; 2014 Apr; 192(8):3908-3914. PubMed ID: 24639348
[TBL] [Abstract][Full Text] [Related]
18. Glycosaminoglycans mediate cell surface oligomerization of chemokines.
Hoogewerf AJ; Kuschert GS; Proudfoot AE; Borlat F; Clark-Lewis I; Power CA; Wells TN
Biochemistry; 1997 Nov; 36(44):13570-8. PubMed ID: 9354625
[TBL] [Abstract][Full Text] [Related]
19. Differential binding of chemokines to glycosaminoglycan subpopulations.
Witt DP; Lander AD
Curr Biol; 1994 May; 4(5):394-400. PubMed ID: 7922353
[TBL] [Abstract][Full Text] [Related]
20. Small molecule inhibitors of protein interaction with glycosaminoglycans (SMIGs), a novel class of bioactive agents with anti-inflammatory properties.
Harris N; Kogan FY; Il'kova G; Juhas S; Lahmy O; Gregor YI; Koppel J; Zhuk R; Gregor P
Biochim Biophys Acta; 2014 Jan; 1840(1):245-54. PubMed ID: 24060749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
